Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors

Abstract

Cancer diagnoses have been increasing worldwide, and solid tumors are among the leading contributors to patient mortality, creating an enormous burden on the global healthcare system. Cancer is responsible for around 10.3 million deaths worldwide. Solid tumors are one of the most prevalent cancers observed in recent times. On the other hand, early diagnosis is a significant challenge that could save a person's life. Treatment with existing methods has pitfalls that limit the successful elimination of the disorder. Though nanoparticle-based imaging and therapeutics have shown a significant impact in healthcare, current methodologies for solid tumor treatment are insufficient. There are multiple complications associated with the diagnosis and management of solid tumors as well. Recently, surface-conjugated nanoparticles such as lipid nanoparticles, metallic nanoparticles, and quantum dots have shown positive results in solid tumor diagnostics and therapeutics in preclinical models. Other nanotheranostic material platforms such as plasmonic theranostics, magnetotheranostics, hybrid nanotheranostics, and graphene theranostics have also been explored. These nanoparticle theranostics ensure the appropriate targeting of tumors along with selective delivery of cargos (both imaging and therapeutic probes) without affecting the surrounding healthy tissues. Though they have multiple applications, nanoparticles still possess numerous limitations that need to be addressed in order to be fully utilized in the clinic. In this review, we outline the importance of materials and design strategies used to engineer nanoparticles in the treatment and diagnosis of solid tumors and how effectively each method overcomes the drawbacks of the current techniques. We also highlight the gaps in each material platform and how design considerations can address their limitations in future research directions.

The Impact of Nanomedicine on Soft Tissue Sarcoma Treated by Radiotherapy and/or Hyperthermia: A Review

“…NPs can be administered either intravenously or intratumoraly. Intratumoral injection seems to have a better distribution of NPS, offering a tremendous enhancement in RT dose in the gross tumor volume [ 62 ], whereas intravenous administration seems to have inferior upload inside the cancerous tissue, although organic NPs such as liposomes seem to have sufficient tropism for the solid tumor [ 63 ]. In terms of clinical practice, it is important to consider that NPs may need to be administered during each treatment session.…”

Advances in the Optimization of Fe Nanoparticles: Unlocking Antifungal Properties for Biomedical Applications

“…Fe NPs have a long history of clinical usage, and their use has produced a wide range of therapeutic products [216,217]. While conventional treatments, such as surgery for solid tumors, antitumor drugs, and radiation, have undoubtedly been effective in preserving lives, it is important to acknowledge the significant adverse side effects they can cause [218,219]. In recent years, there has been a growing interest in the application of magnetic NPs in the field of biomedicine [220,221].…”